The ANLIVA™ platform.
ANLIVA™ is a digital health platform aiming to provide automatic, reliable indications of Parkinson’s disease treatment efficiency. We are creating ANLIVA to assist clinicians that need to make the most of precision treatments.
Our goal is to attain the best therapeutical effect in each patient as fast as possible, with the least risk of side effects. With self-tracking and robust symptom monitoring more accessible to both clinicians and patients, ANLIVA also supports the ongoing shift to patient-centered care.
Stay up-to-date
Sign up to receive updates on our latest developments.
Turn Parkinson’s disease symptoms into shared knowledge.
As Parkinson’s disease progresses over the years, increasingly precise treatment needs to be tailored and regularly adjusted to individual patient needs.
Today, caregivers rely on visual symptoms and general guidelines to recommend and fine-tune treatment. Assessments can become more or less subjective, based on the clinician’s experience.
Optimizing late-stage Parkinson’s treatments can be a challenging task. Besides motor symptoms, sleep disturbances, pain, and psychological complications are not uncommon. In older patients, other age-related diseases like dementia also need to be considered.
The ANLIVA platform transforms Parkinson-related symptoms into progressive, clinical biomarkers that indicate treatment efficiency.
Eye motor control and arm/hand movements are captured using off-the-shelf hardware and evaluated in the cloud. Symptoms can be captured both during healthcare contacts and by the patients themselves to aid self-monitoring.
Patients and caregivers share the same view of symptom development and history, both during- and in-between planned visits.
Reliable clinical biomarkers also allow us to seek collaborations for AI-assisted optimization of Deep brain stimulation (DBS), and other precision treatments for Parkinson’s disease.
Sensor readings are recorded to a cloud service. The data is used for symptom quantification using proprietary algorithms. Patients and caregivers receive individualized reports, analysis, and statistics based on an AI-powered cloud solution.
Who can benefit from ANLIVA?
ANLIVA provides a shared, up-to-date picture of treatment efficiency. Patients and clinicians can learn together from everyday changes and long-time trends.
- Parkinson’s disease patients can get a better quality of life through optimized individual treatment.
- With an objective daily insight into their treatment, patients can come better prepared for their next contact with the clinic.
- Clinicians get quick, accessible, and objective decision support for treatment decisions.
- Caregivers can free up hospital resources.
Reliable symptom tracking and analysis can also assist clinical trials to support the development of new Parkinson’s disease treatments.
Market launch in 2024
Our proprietary mathematical models are developed under Professor Alexander Medvedev at Uppsala University, supported with ~$1M funding from the Swedish innovation agency Vinnova.
Stardots has raised expansion capital with VNV Global AB as a leading investor with ~$4M to prepare for market launch. Other investors in Stardots include Uppsala University Invest AB and Stockholm University Holding AB. The ANLIVA platform is to be CE- and FDA approved and ready for launch in EU/U.S. early 2024
-
A solution like Stardots is developing is of the utmost importance and the only way if we want a state of knowledge that enables us to obtain better treatment methods than those that exist today.
-
My patients would really benefit from improved symptom monitoring in their everyday life so Stardots’ approach is promising.